Patients with COVID-19 have an increased risk of venous thromboembolism (VTE), but the best strategy for the prevention and care of VTE remains elusive. Observational studies have suggested that empiric full anticoagulation in patients with COVID-19 is ineffective or indeed harmful. Recently, however, multiple large platform trials (ACTIV-4a, ATTACC, and REMAP-CAP) have provided surprising new evidence in favor of full anticoagulation in selected populations. In this episode, our panel of experts review the newest data and provide insights on how we can best care for patients in this next phase of the pandemic. (Originally recorded April 1, 2021) Moderator: Jean M. Elwing, MD, FCCP. Panelists: Sandeep Sahay, MD; Dana Kay, DO; Parth Rali, MD; and Vijay Balasubramanian, MD. For more tools to help in the fight against COVID-19, visit CHEST’s COVID-19 Resource Center at chestnet.org/COVID19.